Cartesian Therapeutics Q2 2026 net income $15.8M; cash $149.3M; Phase 3 AURORA data expected 1Q27

Cartesian Therapeutics, Inc.

2026-Q2 EPS reported -$0.83 revenue$78,000

Net income $15.8M ($0.47 basic EPS) vs $15.9M prior year; R&D expenses $20.4M, G&A $8.7M.
Cash $149.3M as of June 30, 2026; cash runway into 2028 via up to $150M K2HV credit facility (first $50M funded).
Phase 3 AURORA trial of Descartes-08 in MG on track; data expected 1Q27, BLA filing mid-2027.
Phase 2 TRITON myositis data subset expected 1H27; Phase 1/2 HELIOS pediatric JDM data expected 1H27.
New licensing agreement with WestGene for in vivo CAR-T; Phase 1 trial 2H26 with data 1H27.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.